Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVOVA-1 + granulocyte-macrophage colony-stimulating factor
- Development stage
- Unknown
- Lead developer
- Aivita Biomedical
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intradermal, Subcutaneous
01
Overview
AVOVA-1 + granulocyte-macrophage colony-stimulating factor is a combination immunotherapy for advanced ovarian, fallopian tube, and primary peritoneal carcinoma. AVOVA-1 is an autologous dendritic cell vaccine preparation where dendritic cells are loaded with autologous tumor-associated antigens isolated from the patient’s own tumor-initiating cells[1][3][9]. This vaccination aims to present patient-specific tumor antigens to the immune system, stimulating an adaptive immune response against residual tumor cells. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is included as an immune adjuvant to enhance dendritic cell function and promote immune activation. This platform is developed primarily by AiVita Biomedical and its partners, and targets patients following standard debulking surgery and chemotherapy. The combination is being studied in Phase II clinical trials for recurrent or advanced epithelial ovarian, fallopian tube, and primary peritoneal carcinoma after primary therapy[1][3][7][9].
- Other names
- Ovapuldencel-T + granulocyte-macrophage colony-stimulating factor
Beyond the preview
Go deeper on AVOVA-1 + granulocyte-macrophage colony-stimulating factor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVOVA-1 + granulocyte-macrophage colony-stimulating factor.